Lisata Therapeutics Future Growth

Future criteria checks 0/6

Lisata Therapeutics's earnings are forecast to decline at 8.5% per annum while its annual revenue is expected to grow at 90.5% per year. EPS is expected to grow by 11.6% per annum.

Key information

-8.5%

Earnings growth rate

11.6%

EPS growth rate

Biotechs earnings growth	30.2%
Revenue growth rate	90.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	21 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8NE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-28	N/A	N/A	2
12/31/2025	N/A	-30	N/A	N/A	2
12/31/2024	N/A	-26	N/A	N/A	2
3/31/2024	N/A	-20	-19	-19	N/A
12/31/2023	N/A	-21	-20	-20	N/A
9/30/2023	N/A	-21	-22	-22	N/A
6/30/2023	N/A	-54	-23	-23	N/A
3/31/2023	N/A	-56	-24	-24	N/A
12/31/2022	N/A	-54	-21	-21	N/A
9/30/2022	N/A	-55	-20	-19	N/A
6/30/2022	N/A	-25	-21	-20	N/A
3/31/2022	N/A	-24	-20	-20	N/A
12/31/2021	N/A	-27	-22	-22	N/A
9/30/2021	N/A	-26	-23	-23	N/A
6/30/2021	N/A	-25	-22	-22	N/A
3/31/2021	N/A	-12	-13	-13	N/A
12/31/2020	N/A	-8	-9	-9	N/A
9/30/2020	N/A	-8	-7	-7	N/A
6/30/2020	N/A	-7	-8	-8	N/A
3/31/2020	N/A	-19	-18	-18	N/A
12/31/2019	N/A	-19	-19	-19	N/A
9/30/2019	N/A	-18	-18	-18	N/A
6/30/2019	N/A	-17	-18	-18	N/A
3/31/2019	N/A	-16	-19	-19	N/A
12/31/2018	N/A	-16	-20	-20	N/A
9/30/2018	N/A	-17	-21	-21	N/A
6/30/2018	N/A	-17	-23	-22	N/A
3/31/2018	N/A	-14	-17	-17	N/A
12/31/2017	N/A	-16	N/A	-21	N/A
9/30/2017	N/A	-18	N/A	-20	N/A
6/30/2017	N/A	-20	N/A	-20	N/A
3/31/2017	-7	-26	N/A	-26	N/A
12/31/2016	N/A	-31	N/A	-24	N/A
9/30/2016	8	-59	N/A	-29	N/A
6/30/2016	13	-64	N/A	-32	N/A
3/31/2016	27	-74	N/A	-33	N/A
12/31/2015	22	-81	N/A	-39	N/A
9/30/2015	20	-59	N/A	-41	N/A
6/30/2015	18	-65	N/A	-46	N/A
3/31/2015	17	-60	N/A	-50	N/A
12/31/2014	18	-55	N/A	-47	N/A
9/30/2014	17	-56	N/A	-43	N/A
6/30/2014	16	-48	N/A	-36	N/A
3/31/2014	16	-44	N/A	-31	N/A
12/31/2013	15	-39	N/A	-27	N/A
9/30/2013	13	-39	N/A	-29	N/A
6/30/2013	14	-40	N/A	-26	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8NE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8NE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8NE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8NE is forecast to have no revenue next year.

High Growth Revenue: 8NE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8NE's Return on Equity is forecast to be high in 3 years time

Lisata Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

New 90-day high: €2.84

Caladrius Biosciences, Inc. Treats First Patient in the Phase 2B Freedom Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Caladrius Biosciences, Inc. Announces Executive Changes

New 90-day low: €1.24

Caladrius Biosciences, Inc. Appoints Anne Whitaker to Board of Directors

New 90-day low: €1.27

Caladrius Biosciences, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

Insider recently bought €85k worth of stock

New 90-day low - €1.40

Caladrius Biosciences, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies